Product
PLN-101095
1 clinical trial
1 indication
Indication
Metastatic Solid TumorClinical trial
A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on PembrolizumabStatus: Recruiting, Estimated PCD: 2025-06-01